Principal Financial Group Inc. increased its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 7.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,845 shares of the company’s stock after acquiring an additional 8,196 shares during the period. Principal Financial Group Inc. owned approximately 0.11% of Henry Schein worth $9,054,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. AQR Capital Management LLC increased its position in Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Henry Schein during the first quarter valued at $676,000. Cetera Investment Advisers raised its position in shares of Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock worth $406,000 after purchasing an additional 637 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Henry Schein by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock worth $16,154,000 after purchasing an additional 1,669 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.
Henry Schein Price Performance
HSIC opened at $85.47 on Monday. The company’s 50-day simple moving average is $80.98 and its two-hundred day simple moving average is $78.03. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The stock has a market capitalization of $9.74 billion, a P/E ratio of 25.82, a P/E/G ratio of 1.65 and a beta of 0.81. Henry Schein, Inc. has a 52-week low of $61.94 and a 52-week high of $89.34.
Insider Buying and Selling
In related news, Director William K. Daniel bought 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.89% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have weighed in on HSIC shares. Wall Street Zen lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Thursday, June 11th. Citigroup assumed coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target for the company. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research report on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $88.62.
Check Out Our Latest Research Report on Henry Schein
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Recommended Stories
- Five stocks we like better than Henry Schein
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
